Healthcare Industry News: Prolaris
News Release - May 1, 2014
Myriad to Launch EndoPredict(R) in Canada
A Next-Generation, Multigene Prognostic Test for Patients Diagnosed With Breast CancerZURICH, Switzerland and MONTREAL, May 1, 2014 -- (Healthcare Sales & Marketing Network) -- Myriad Genetics GmbH today announced the launch of EndoPredict in Canada and presented EndoPredict during the 5th International Symposium on Hereditary Breast and Ovarian Cancer held April 23-25, 2014 at the Centre Mont-Royal, Montreal, Canada.
EndoPredict is a next-generation, multi-gene prognostic test for patients diagnosed with breast cancer. EndoPredict provides physicians with information to devise personalized treatment plans for their breast cancer patients. EndoPredict was shown to accurately predict cancer-specific disease progression and metastasis in multiple clinical outcome studies with more than 2,200 patients.
In contrast to first-generation multi-gene prognostic tests, EndoPredict detects the likelihood of late metastases (i.e., metastasis formation after more than five years) and, therefore, can guide treatment decisions regarding the need for chemotherapy as well as extended anti-hormonal therapy. Accordingly, therapy decisions backed by EndoPredict confer a high level of diagnostic safety.
"Myriad is expanding our international presence, and we are pleased to make EndoPredict widely accessible to patients in Canada," said Gary King, executive vice president, International Operations, Myriad Genetics. "We are committed to providing the highest quality life-saving products. EndoPredict is backed by extensive clinical evidence with thousands of patients and is an ideal platform for use by clinical pathologists who wish to perform testing in their own laboratories, providing cost-effective solutions for healthcare providers."
About Myriad Genetics GmbH
Myriad Genetics GmbH is based in Zurich, Switzerland and is the international subsidiary of Myriad Genetics Inc., a leading molecular diagnostic company dedicated to making a difference in patients' lives through the discovery and commercialization of transformative tests to assess a person's risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. Myriad's molecular diagnostic tests are based on an understanding of the role genes play in human disease and were developed with a commitment to improving an individual's decision making process for monitoring and treating disease. Myriad is focused on strategic directives to introduce new products, including companion diagnostics, as well as expanding internationally. For more information on how Myriad Genetics GmbH is making a difference, please visit the Company's website: www.myriad.ch.
Myriad, the Myriad logo, Prolaris, Myriad myPath, Myriad myPlan, and Myriad myRisk are trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and foreign countries. MYGN-F, MYGN-G. EndoPredict is a trademark or registered trademark of Sividon.
Safe Harbor Statement
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the EndoPredict test and Myriad's partnering with Sividon to market the EndoPredict test in Europe, Canada and worldwide; and the Company's strategic directives under the caption "About Myriad Genetics." These "forward-looking statements" are management's present expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those described in the forward-looking statements. These risks include, but are not limited to: the risk that sales and profit margins of our existing molecular diagnostic tests and companion diagnostic services may decline or will not continue to increase at historical rates; risks related to changes in the governmental or private insurers reimbursement levels for our tests; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and companion diagnostic services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and companion diagnostic services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and companion diagnostic services tests and any future tests are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities; risks related to public concern over our genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to increased competition and the development of new competing tests and services; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents; risks related to changes in intellectual property laws covering our molecular diagnostic tests and companion diagnostic services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decision in the lawsuit brought against us by the Association for Molecular Pathology et al; risks of new, changing and competitive technologies and regulations in the United States and internationally; and other factors discussed under the heading "Risk Factors" contained in Item 1A of our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law.
Source: Myriad Genetics
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
